Literature DB >> 22865512

Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis.

James T Teo1, Mark J Edwards, Kailash Bhatia.   

Abstract

It has been 50 years since the first patients with tardive dyskinesia (TD) were described, but the pathophysiology is only partially understood and effective treatments have remained elusive. Newer atypical antipsychotics with less nonspecific activity at dopamine receptors have not heralded the end of tardive dyskinesia and merely highlight the incomplete understanding of the disorder. We present an overview of the existing pathophysiology of the disorder and incorporate recent developments in genetics and the study of human synaptic plasticity in other hyperkinetic movement disorders. We propose a hypothesis that dopamine-receptor sensitization and altered function of the N-methyl-D-aspartate receptor produces maladaptive synaptic plasticity, which allows the encoding of abnormal motor programs, and propose studies that would falsify or support this hypothesis. In conclusion, a maladaptive synaptic plasticity" hypothesis goes some way toward filling in the gaps of existing theories of TD with the pathophysiology of other hyperkinetic movement disorders. © 2012 Movement Disorder Society.
Copyright © 2012 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22865512     DOI: 10.1002/mds.25107

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  27 in total

Review 1.  [Antipsychotic-induced tardive syndromes].

Authors:  W Wolfgang Fleischhacker; Alex Hofer; Christian Jagsch; Walter Pirker; Georg Psota; Hans Rittmannsberger; Klaus Seppi
Journal:  Neuropsychiatr       Date:  2016-08-31

2.  Repetitive transcranial magnetic stimulation for treatment of tardive syndromes: double randomized clinical trial.

Authors:  Eman M Khedr; Bastawy Al Fawal; Ahmed Abdelwarith; Mostafa Saber; John C Rothwell
Journal:  J Neural Transm (Vienna)       Date:  2018-10-13       Impact factor: 3.575

Review 3.  Clinical Features, Neuroimaging, and Levodopa-Responsiveness in Holmes' Tremor: A Video-Based Case-Series with a Review of the Literature.

Authors:  Anumeha Mishra; Sanjay Pandey
Journal:  Mov Disord Clin Pract       Date:  2022-07-07

Review 4.  The role of neuroplasticity in dopaminergic therapy for Parkinson disease.

Authors:  Xiaoxi Zhuang; Pietro Mazzoni; Un Jung Kang
Journal:  Nat Rev Neurol       Date:  2013-04-16       Impact factor: 42.937

Review 5.  Current Methods for the Treatment and Prevention of Drug-Induced Parkinsonism and Tardive Dyskinesia in the Elderly.

Authors:  Carlos Estevez-Fraga; Paul Zeun; Jose Luis López-Sendón Moreno
Journal:  Drugs Aging       Date:  2018-11       Impact factor: 3.923

6.  Striatal cholinergic interneurons and D2 receptor-expressing GABAergic medium spiny neurons regulate tardive dyskinesia.

Authors:  Tanuja Bordia; Danhui Zhang; Xiomara A Perez; Maryka Quik
Journal:  Exp Neurol       Date:  2016-09-19       Impact factor: 5.330

7.  Hyperkinetic manifestations in superficial siderosis: evidence for pathogenic network disruption.

Authors:  Antonio De Mase; Dario Saracino; Vincenzo Andreone
Journal:  Neurol Sci       Date:  2020-10-01       Impact factor: 3.307

Review 8.  Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.

Authors:  Nicki Niemann; Joseph Jankovic
Journal:  Drugs       Date:  2018-04       Impact factor: 9.546

9.  Anticholinergic drugs rescue synaptic plasticity in DYT1 dystonia: role of M1 muscarinic receptors.

Authors:  Marta Maltese; Giuseppina Martella; Graziella Madeo; Irene Fagiolo; Annalisa Tassone; Giulia Ponterio; Giuseppe Sciamanna; Pierre Burbaud; P Jeffrey Conn; Paola Bonsi; Antonio Pisani
Journal:  Mov Disord       Date:  2014-09-04       Impact factor: 10.338

Review 10.  Spotlight on Oculogyric Crisis: A Review.

Authors:  Pankaj Mahal; Navratan Suthar; Naresh Nebhinani
Journal:  Indian J Psychol Med       Date:  2020-09-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.